Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1984 6
1985 9
1986 6
1987 4
1988 8
1989 6
1990 9
1991 10
1992 11
1993 12
1994 16
1995 11
1996 10
1997 15
1998 7
1999 16
2000 13
2001 20
2002 13
2003 7
2004 16
2005 18
2006 25
2007 12
2008 9
2009 8
2010 11
2011 13
2012 7
2013 6
2014 6
2015 5
2016 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

330 results
Results by year
Filters applied: . Clear all
Page 1
TMAO is both a biomarker and a renal toxin.
Fogelman AM. Fogelman AM. Circ Res. 2015 Jan 30;116(3):396-7. doi: 10.1161/CIRCRESAHA.114.305680. Circ Res. 2015. PMID: 25634968 Free PMC article. No abstract available.
Pathogenesis of atherosclerosis.
Navab M, Fogelman AM, Berliner JA, Territo MC, Demer LL, Frank JS, Watson AD, Edwards PA, Lusis AJ. Navab M, et al. Am J Cardiol. 1995 Sep 28;76(9):18C-23C. doi: 10.1016/s0002-9149(99)80466-4. Am J Cardiol. 1995. PMID: 7572682 Review.
The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
Namiri-Kalantari R, Gao F, Chattopadhyay A, Wheeler AA, Navab KD, Farias-Eisner R, Reddy ST. Namiri-Kalantari R, et al. Biofactors. 2015 May 6;41(3):153-9. doi: 10.1002/biof.1205. Epub 2015 Jun 13. Biofactors. 2015. PMID: 26072738 Review.
Malondialdehyde, modified lipoproteins, and atherosclerosis.
Haberland ME, Fong D, Cheng L. Haberland ME, et al. Eur Heart J. 1990 Aug;11 Suppl E:100-4. doi: 10.1093/eurheartj/11.suppl_e.100. Eur Heart J. 1990. PMID: 2226517 Review. No abstract available.
Searching for a successful HDL-based treatment strategy.
Reddy ST, Navab M, Anantharamaiah GM, Fogelman AM. Reddy ST, et al. Biochim Biophys Acta. 2014 Jan;1841(1):162-7. Biochim Biophys Acta. 2014. PMID: 24466591 Review.
330 results
Jump to page
Feedback